Greetings!
Called "Branded Generics", they are generic drugs that carry a big pharma name and are gaining increasing popularity in emerging markets-especially China, India, and Latin America. Generic drugs already represent 25 percent on average of worldwide pharmaceuticals sales. Thanks to these markets, branded generics are likely to reach up to 75 percent of sales growth within the next 10 years.
That's because overseas consumers respect and trust branded drugs more than local generics. Consumers perceive the latter as being satisfied with lax quality controls, while branded drugs are trusted to have a higher level of quality and effectiveness.
Join the BRANDED GENERICS conference on February 27-28 in Philadelphia to learn about proven business and operating models for branded generics in countries including China, India, Brazil, Russia, Turkey, Mexico, and Korea. Here you'll find the industry's most influential investors, entrepreneurs, and executives from established healthcare companies. Don't miss the chance to find out whether this opportunity for sales expansion is right for you. |
Don't miss out - Register for
Branded Generics for Emerging Markets now!
|
|
Conference Chairman
Richard Dicicco
Chairman
HARVEST MOON PHARMACEUTICALS USA
 BRANDED VS. GENERICS IN RUSSIA Valeria Povolotsky VP of Global Partnering, R-PHARM;
CEO, ADVANCED BIO DESIGN
 BUSINESS AND OPERATION MODELS IN TURKEY Ashish Menocha Head of International Markets
ABDI IBRAHIM
 THE BRANDED GENERICS PROPOSITION -- A MANUFACTURING PERSPECTIVE Anita Shaw Branded Generics Technical Director
MERCK & CO.
 BRANDED GENERICS: A GATEWAY TO INDIA Arvind Mishra, Ph.D. President, Corporate QC/QA and Regulatory Affairs
PARABOLIC DRUGS LTD.
 UNDERSTANDING CHINA'S EVOLVING PHARMACEUTICAL MARKET Jiwen Chen, J.D., LL.M. Attorney-at-Law/ Asia Practice Director
JACOBSON HOLMAN PLLC
 EXPANSION INTO LATIN AMERICA WITH BRANDED GENERICS Daisy Rivera-Muzzio Managing Partner DRM BioPharmSource LLC
|
